February 6, 2019

Improving Alzheimer’s Disease Management: Early Diagnosis and Health Equity Considerations

Hybrid 2021 Alzheimer’s Association International Conference (AAIC)

Utility of AD Biomarkers: Increasing the Certainty of Diagnosis

Kaj Blennow, MD, PhD, discusses the impact of biomarkers in the changing landscape of AD diagnosis, and how amyloid and tau positron emission tomography imaging and cerebrospinal fluid biomarkers can be used to increase diagnostic certainty when used in tandem with clinical assessment. He also outlines the potential role for blood-based biomarkers in the future diagnostic workup. Throughout, Professor Blennow highlights the importance of including underserved and underrepresented populations in AD biomarker research.

Key Learning Objectives from Biogen’s AAIC 2021 Symposium:

  • Highlight the importance of early detection and diagnosis of AD, through appropriate use of cognitive and functional screening tools and biomarker assessments
  • Assess current healthcare system readiness for a paradigm shift to early diagnosis of AD
  • Outline considerations in patient care for underrepresented and underserved populations

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.